Is Schrödinger Stock a Buy Now?
With the frothiness of the artificial intelligence (AI) craze in full swing, Schrödinger (NASDAQ: SDGR) is a biotech that investors should know about now. While many questions remain about the viability of its business model and its ability to grow in the long term in the face of mounting competition, for the moment it's one of the leaders in the field of information technology-driven drug development.
But is right now the best time to make an investment given the market's fervor when it comes to everything remotely associated with AI? Let's investigate in closer detail.
Schrödinger is a leader in the field of technology-assisted drug discovery and development. It uses a combination of molecular modeling, machine learning, and computational chemistry, along with plenty of raw data on structure-function relationships across a swath of different biological molecules, to find promising leads for drug development.
Source Fool.com
